🇯🇵 日本語 🇺🇸 English
3,817 companies 12,975 AI summaries 9,784 risk analyses 5,404 growth scores Register free — watchlist & alerts →
EDINET 4894 Positive Risk Analyzed 📈 Growth 7/10

Cuorips Inc.

Semi-Annual Report - 11th Term(2026/04/01 - 2027/03/31) ／ 2026-11-13 16:33

Covers EDINET statutory filings (TDNET timely disclosures / earnings flashes are not included).

EarningsCapital RaiseNew ProductNew MarketCapacityDemand
AI Summary 2026-11-13 16:37

Regenerative medicine developer. Received conditional approval for Reheart (iPS-derived cardiac cell sheet) in March 2026; insurance coverage activated September 2026 with world-first patient transplant. Q1 revenue declined 98.2% to ¥52M, operating loss ¥69M. Raised ¥2.99B via third-party allotment and ¥1.0B bonds. FY2027 revenue guidance +154.3%.

KEY POINTS
  • Reheart insurance coverage achieved (Sept 2026) and world-first iPS cell-derived product patient implant performed—transition to commercialization phase
  • Secured ¥3.99B in funding via third-party capital raise (¥299M) and bond issuance (¥1.0B); cash position ¥6.77B
  • Q1 FY2026 revenue ¥52M (−98.2% YoY), but FY2027 guidance projects +154.3% growth driven by Reheart commercialization and global expansion
📊 Revenue
Revenue −98.2% (¥193M → ¥52M) [6-month period]
💰 Operating profit
Operating loss widened −38.2% (¥495M loss → ¥685M loss)
🔮 Outlook
FY2027 revenue guidance +154.3%. Plans Reheart commercialization in Japan and Asia-Pacific, US pivotal trials, and catheter-based cell delivery pipeline advancement.
📈 Growth outlook 📈 Growth 7/10
Significant growth expected from FY2027 onwards driven by Reheart commercialization in Japan, US market entry preparation, and international expansion. Multiple pipeline programs (catheter delivery, small-molecule regeneration factors) support medium-term trajectory.
Growth drivers
  • Reheart insurance coverage enabling patient demand realization and market creation in Japan
  • Proof-of-concept advancement in US catheter-based iPS-derived cell delivery (Stanford collaboration)
  • Pilot-scale manufacturing facility operational using government subsidies for future CDMO scale-up
  • New partnership with Osaka University for hepatic disease regeneration factor development
Risk and growth scores and tags are AI-generated estimates from analyzing the disclosure. They are not guarantees of fact, nor investment advice or recommendations. Make investment decisions at your own discretion.
⚠️ Extracted Risk Factors
CategoryDescriptionScoreNew
Earnings Deterioration Risk If Reheart sales underperform guidance, high operating losses may persist or worsen. Adoption rate in insurance-covered procedures and patient enrollment pace remain uncertain. 8/10 NEW
Supply Chain Risk Stable supply and quality assurance of cardiac cells critical. Delays in manufacturing facility scale-up could result in lost sales opportunities as demand grows. 7/10 NEW
Regulatory Risk Regenerative medicine regulatory landscape evolving rapidly. US FDA review outcomes could materially impact development timelines and capital requirements. 7/10 NEW
Technology Risk Long-term safety data on iPS-derived products remains limited. Unexpected adverse events or immune reactions could halt commercialization. 7/10 NEW
Funding Risk Operating cash outflow persists (¥784M for 6 months). If burn continues beyond FY2027, additional capital raises will be required; market conditions may tighten. 6/10 NEW
Competitive Intensity Risk Cardiac disease treatment attracts major pharma interest. Large investors like Daiichi Sankyo may develop competing therapies, pressuring market share. 6/10 NEW
Market Risk Actual treatment demand for ischemic cardiomyopathy may fall short of projections. Insurance reimbursement pressure could reduce revenue per patient. 5/10 NEW
Legal/Compliance Risk Enhanced regulatory scrutiny on informed consent and safety reporting for regenerative products. Administrative penalties for non-compliance. 4/10
8/10 NEW Earnings Deterioration Risk
If Reheart sales underperform guidance, high operating losses may persist or worsen. Adoption rate in insurance-covered procedures and patient enrollment pace remain uncertain.
7/10 NEW Supply Chain Risk
Stable supply and quality assurance of cardiac cells critical. Delays in manufacturing facility scale-up could result in lost sales opportunities as demand grows.
7/10 NEW Regulatory Risk
Regenerative medicine regulatory landscape evolving rapidly. US FDA review outcomes could materially impact development timelines and capital requirements.
7/10 NEW Technology Risk
Long-term safety data on iPS-derived products remains limited. Unexpected adverse events or immune reactions could halt commercialization.
6/10 NEW Funding Risk
Operating cash outflow persists (¥784M for 6 months). If burn continues beyond FY2027, additional capital raises will be required; market conditions may tighten.
6/10 NEW Competitive Intensity Risk
Cardiac disease treatment attracts major pharma interest. Large investors like Daiichi Sankyo may develop competing therapies, pressuring market share.
5/10 NEW Market Risk
Actual treatment demand for ischemic cardiomyopathy may fall short of projections. Insurance reimbursement pressure could reduce revenue per patient.
4/10 Legal/Compliance Risk
Enhanced regulatory scrutiny on informed consent and safety reporting for regenerative products. Administrative penalties for non-compliance.
X LinkedIn Threads Bluesky Facebook
Track Japanese disclosures with JSIGNAL

AI summaries, risk & growth analysis, watchlist alerts and a screener for every Japanese listed company.

Start free — 30-day trial Login